<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
  <title><![CDATA[Stem Lab Zone]]></title>
  <link>https://stemplabzone.com/</link>
  <description><![CDATA[Stem Lab Zone. Tokyo stem cell analysis laboratory. Flow cytometry, cryopreservation, and regenerative medicine consultation. Registered under Japan's Act on the Safety of Regenerative Medicine.]]></description>
  <language>en</language>
  <atom:link href="https://stemplabzone.com/feed.xml" rel="self" type="application/rss+xml" />
  <item>
    <title><![CDATA[Cryopreservation at -196°C: what the temperature actually does to a stem cell and why the rate of freezing matters]]></title>
    <link>https://stemplabzone.com/notes/cryopreservation-temperature-stem-cell-biology.html</link>
    <guid isPermaLink="true">https://stemplabzone.com/notes/cryopreservation-temperature-stem-cell-biology.html</guid>
    <description><![CDATA[Most people who store stem cells picture a simple transaction: the sample goes in, the cold keeps it safe, it comes back when needed. The reality is considerably more violent. Between 37°C and -196°C, a cell passes through at least three distinct physical crises, any one of which can destroy it entirely. The biophysics involved — osmotic collapse, intracellular ice nucleation, and what cryobiologists call the "two-factor hypothesis" — are genuinely fascinating, and understanding them changes how you think about what a laboratory is actually doing when it manages your sample. This article walks through the thermodynamics and chemistry of controlled-rate freezing in plain terms, because the choices made during cooling are not arbitrary protocols — they are responses to specific, measurable dangers at specific temperatures.]]></description>
    <pubDate>Wed, 15 Jul 2026 00:00:00 GMT</pubDate>
  </item>
  <item>
    <title><![CDATA[How to read a flow cytometry report: a guide for patients and non-specialist physicians]]></title>
    <link>https://stemplabzone.com/notes/how-to-read-flow-cytometry-report.html</link>
    <guid isPermaLink="true">https://stemplabzone.com/notes/how-to-read-flow-cytometry-report.html</guid>
    <description><![CDATA[A flow cytometry report lands on a desk and, for most people who are not hematologists, it reads like a decoded transmission from another discipline — columns of percentages, cryptic CD numbers, gates that look like abstract art. That gap matters clinically, because misreading a single value can push a patient toward an unnecessary biopsy or, worse, delay a referral that should have happened last week. This walkthrough takes a standard CD34+ report, the kind issued after a peripheral blood or bone marrow collection, and explains each major panel in plain language. The goal is not to replace specialist interpretation but to give patients and generalist physicians enough vocabulary to ask the right questions in the room. Stem Lab Zone's team reviewed anonymized report formats from multiple accredited South African hematology laboratories and found that the three panels causing the most confusion were CD34 enumeration, the lymphocyte scatter gate, and the viability readout — so those get the most space here.]]></description>
    <pubDate>Mon, 18 May 2026 00:00:00 GMT</pubDate>
  </item>
  <item>
    <title><![CDATA[What to expect when you send a bone marrow aspirate to an external laboratory in Japan]]></title>
    <link>https://stemplabzone.com/notes/bone-marrow-aspirate-external-laboratory-japan.html</link>
    <guid isPermaLink="true">https://stemplabzone.com/notes/bone-marrow-aspirate-external-laboratory-japan.html</guid>
    <description><![CDATA[Sending a bone marrow aspirate to an external laboratory sounds straightforward until the courier calls at 7 a.m. to ask whether the specimen is classified as a Category B biological substance under IATA P650, and your answer determines whether the package gets loaded or held at Narita. For many clinicians in Japan, the referral workflow is pieced together from internal memos, verbal hand-offs from senior colleagues, and the occasional phone call to a lab coordinator who is also managing three other urgent samples. This guide exists to compress that learning curve. It covers everything from the moment the needle is withdrawn to the moment a structured report lands in your hospital information system, with particular attention to the regulatory checkpoints that are specific to Japan's Pharmaceutical and Medical Device Act framework and the guidelines issued by the Japanese Society of Laboratory Hematology.]]></description>
    <pubDate>Sun, 02 Nov 2025 00:00:00 GMT</pubDate>
  </item>
  <item>
    <title><![CDATA[Building a reference dataset from scratch: the methodology behind our 1,400-sample cohort]]></title>
    <link>https://stemplabzone.com/notes/building-reference-dataset-stem-cell-cohort.html</link>
    <guid isPermaLink="true">https://stemplabzone.com/notes/building-reference-dataset-stem-cell-cohort.html</guid>
    <description><![CDATA[Every reference dataset has a creation myth — the clean, compressed version that appears in the methods section of a paper. Ours is not that story. Between January 2019 and March 2025, the team at Stem Lab Zone collected, processed, and annotated 1,400 biological samples to build what is now the lab's primary in-house reference cohort for stem cell characterization work. The process involved four recruitment cycles, two protocol revisions, one IRB amendment that cost us eight weeks of momentum, and a demographic composition that still keeps the team up at night. This article is an attempt to document what actually happened, so that anyone who uses the dataset — or who is building something similar — understands exactly what they are working with.]]></description>
    <pubDate>Wed, 03 Sep 2025 00:00:00 GMT</pubDate>
  </item>
  <item>
    <title><![CDATA[Seasonal variation in peripheral blood CD34+ counts: five years of intake data from our Tokyo laboratory]]></title>
    <link>https://stemplabzone.com/notes/seasonal-variation-cd34-peripheral-blood-tokyo.html</link>
    <guid isPermaLink="true">https://stemplabzone.com/notes/seasonal-variation-cd34-peripheral-blood-tokyo.html</guid>
    <description><![CDATA[Every August, something odd happens in our intake logs. The CD34+ counts — the progenitor cells we track as a primary quality indicator for peripheral blood donations — slide downward in a pattern that repeats so reliably it started to feel like a calendar event rather than random noise. We noticed it first in the 2020 data, dismissed it, then saw it again in 2021 and 2022, at which point it became hard to ignore. So in early 2024, we sat down with five full years of intake records, 2,847 samples collected between January 2019 and December 2023, and asked the question properly: is there a real seasonal signal in peripheral blood CD34+ counts, and if so, what is driving it? The answer turned out to be more complicated than we expected, and the implications touch on everything from donor scheduling to mobilization protocols.]]></description>
    <pubDate>Sun, 27 Apr 2025 00:00:00 GMT</pubDate>
  </item>
  <item>
    <title><![CDATA[What Japan's Act on the Safety of Regenerative Medicine actually requires from a Type II provider]]></title>
    <link>https://stemplabzone.com/notes/japan-regenerative-medicine-act-type-ii-provider.html</link>
    <guid isPermaLink="true">https://stemplabzone.com/notes/japan-regenerative-medicine-act-type-ii-provider.html</guid>
    <description><![CDATA[Japan's Act on the Safety of Regenerative Medicine (再生医療等安全性確保法, enacted 2014) created a three-tier classification system that sorts regenerative medicine providers by the risk level of the cells they work with. Most English-language commentary stops at a single paragraph describing the tiers, which leaves practitioners with a frustratingly incomplete picture of their actual legal obligations. The Type II classification sits in the middle of that ladder, and the middle is always the messiest place to be: too risky for the lightest touch, not risky enough to attract the scrutiny that clarifies everything. What follows is a close reading of the statutory text, the accompanying Cabinet Office ordinances, and the Ministry of Health, Labour and Welfare (MHLW) guidance documents published through early 2025, aimed at anyone who needs to understand what operating as a Type II provider actually looks like in practice.]]></description>
    <pubDate>Wed, 12 Mar 2025 00:00:00 GMT</pubDate>
  </item>
</channel>
</rss>
